4basebio PLC 4BB
LSE · United Kingdom · Health Technology
GBp 562.500.00 (0.00%)
Market closed· · GBp · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · GBp · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Collaboration extends existing relationship with the Tier 1 pharmaceutical customer into cell therapy programsEnd-to-end supply chain combines 4basebio's proprietary opDNA® enzymatic DNA starting material with TriLink's industry-leading GMP mRNA manufacturing capabilities and proprietary CleanCap® co-transcriptional capping technology CAMBRIDGE, UK – 28 September, 2026 – 4basebio PLC (AIM: 4BB), a specialist in enzymatically-produced DNA for new genetic medicines, announces they will supply clin
Manufacturing hurdles are just one challenge the industry must overcome to commercialize personalized mRNA cancer vaccines.
Commercial collaboration combines 4basebio’s synthetic DNA technology with Genezen’s viral vector development and manufacturing expertise to support gene therapy programs from early development through clinical and commercial manufacturing. CAMBRIDGE, UK and INDIANAPOLIS, IN – 26 August 2026 – 4basebio PLC (AIM: 4BB), a specialist in enzymatically-produced, cell-free DNA for new genetic medicines, and Genezen, a best-in-class viral vector contract development and manufacturing organization (CDMO
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.